This segment focuses on the research and development of MBTs, specifically CB4211, for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. Research and development activities include preclinical studies, Phase Ia/Ib clinical trials, and formulation development. The technology platform centers around the use of refined analogs of the MOTS-c mitochondrial-derived peptide. The primary therapeutic area is metabolic diseases, with the goal of improving liver health and reducing obesity-related complications. Patient impact is addressed through potential improvements in liver function, reduced inflammation, and weight management. CohBar aims to establish a competitive advantage through its unique MBT approach. Future opportunities include expanding the application of MBTs to other metabolic disorders. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. This segment does not have any current partnerships.

This segment encompasses preclinical research and development efforts focused on developing MBT analogs for various diseases. This includes CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. Research activities involve in vitro and in vivo studies to assess efficacy and safety. The technologies employed include peptide synthesis, formulation development, and preclinical testing in relevant disease models. The therapeutic areas covered include fibrotic diseases, acute respiratory distress syndrome (ARDS), cancer, and orphan diseases. The patient impact is aimed at addressing unmet medical needs in these areas. Market positioning involves differentiating CohBar's MBT approach from other therapeutic modalities. Future opportunities include expanding the pipeline to address additional diseases. Regulatory and clinical aspects involve preparing for future clinical trials. This segment has a preclinical collaboration with NIAID to evaluate CB5064 analogs for the treatment of COVID-19 ARDS.